Longeveron (LGVN) Operating Margin (2020 - 2026)
Longeveron (LGVN) recorded quarterly Operating Margin of 1199.75% in Q1 2026, up 18.89% quarter-over-quarter from 1479.18% in Q4 2025, and up 16009.0% on a YoY basis from N/an in Q1 2025.
Longeveron (LGVN) Operating Margin (2020 - 2026) Analysis & Trends
Longeveron's Operating Margin history runs 7 years deep, the most recent figure standing at 1199.75% for Q1 2026.
- In Q1 2026, Operating Margin rose 16009.0% year-over-year to 1199.75%; the TTM figure through Mar 2026 stood at 1881.66% (down 109016.0% YoY), while the FY2025 annual figure was 1942.2%, down 125148.0% from the prior year.
- Operating Margin was 1199.75% for Q1 2026 at Longeveron, up from 1479.18% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 601.42% in Q3 2024 to a low of 8634.92% in Q4 2023.
- Historically, Operating Margin has averaged 2448.69% across 5 years, with a median of 1479.18% in 2025.
- The sharpest annual moves came in 2024 and 2025: Operating Margin soared 792497 bps in 2024, then slumped 473434 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 4331.4% in 2022, then slumped by 99 bps to 8634.92% in 2023, then jumped by 92 bps to 709.95% in 2024, then tumbled by 108 bps to 1479.18% in 2025, then climbed by 19 bps to 1199.75% in 2026.
- The last three Operating Margin figures came in at 1199.75% (Q1 2026), 1479.18% (Q4 2025), and 5335.77% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -1,199.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,199.75% |
| Dec 31, 2025 | -1,479.18% |
| Sep 30, 2025 | -5,335.77% |
| Jun 30, 2025 | -1,707.91% |
| Mar 31, 2025 | -1,359.84% |
| Dec 31, 2024 | -709.95% |
| Sep 30, 2024 | -601.42% |
| Jun 30, 2024 | -747.86% |
| Mar 31, 2024 | -746.35% |
| Dec 31, 2023 | -8,634.92% |
| Sep 30, 2023 | -3,440.67% |
| Jun 30, 2023 | -2,632.26% |
| Mar 31, 2023 | -1,690.32% |
| Dec 31, 2022 | -4,331.40% |
| Sep 30, 2022 | -5,187.00% |
| Jun 30, 2022 | -905.79% |
| Mar 31, 2022 | -917.30% |
| Dec 31, 2021 | -1,929.19% |
| Sep 30, 2021 | -2,114.22% |
| Jun 30, 2021 | -1,035.17% |